tiprankstipranks
Advertisement
Advertisement
Nuvation Bio reports Q1 EPS 1c, consensus 5c
PremiumThe FlyNuvation Bio reports Q1 EPS 1c, consensus 5c
22d ago
Analyst Maintains Buy Rating on Taletrectinib Developer, Reaffirming $17 12-Month Price Target on Strengthening ROS1+ NSCLC Outlook
Premium
Ratings
Analyst Maintains Buy Rating on Taletrectinib Developer, Reaffirming $17 12-Month Price Target on Strengthening ROS1+ NSCLC Outlook
28d ago
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
Premium
The Fly
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
1M ago
Nuvation Bio falls -25.3%
PremiumThe FlyNuvation Bio falls -25.3%
3M ago
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
Premium
Company Announcements
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
3M ago
Nuvation Bio falls -25.6%
Premium
The Fly
Nuvation Bio falls -25.6%
3M ago
Nuvation Bio reports Q4 EPS (11c), consensus (5c)
PremiumThe FlyNuvation Bio reports Q4 EPS (11c), consensus (5c)
3M ago
Nuvation Bio Inc (NUVB) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Nuvation Bio Inc (NUVB) Q4 Earnings Cheat Sheet
3M ago
Nuvation Bio finalizes protocol amendment for study of safusidenib
Premium
The Fly
Nuvation Bio finalizes protocol amendment for study of safusidenib
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100